Siedlecki, Jakob http://orcid.org/0000-0002-0279-4823
Koch, Caroline
Schworm, Benedikt
Liegl, Raffael
Kreutzer, Thomas
Kortuem, Karsten U.
Schumann, Ricarda
Priglinger, Siegfried G.
Wolf, Armin
Article History
Received: 6 May 2020
Accepted: 14 December 2020
First Online: 5 January 2021
Ethics approval and consent to participate
: Institutional review board (University Eye Hospital Munich, Ludwig-Maximilians-University Munich) approval was obtained for this retrospective chart review, and the study adhered to the tenets of the Declaration of Helsinki. All patients provided written consent.
: None applicable, as no uniquely identifying information about a single subject are given.
: No author reports any financial interest relevant to this study.Jakob Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH and Pharm-Allergan GmbH. Jakob Siedlecki received personal consultation fees from Bayer AG.Benedikt Schworm received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation.Thomas C Kreutzer received previous speaker fees from Alcon Pharma GmbH. Thomas C Kreutzer received personal consultation fees from Novartis Pharma GmbH and Bayer AG. Thomas C Kreutzer received travel reimbursement from D.O.R.C. (International) B.V.Raffael Liegl received previous speaker fees from Novartis Pharma GmbH.Karsten Kortuem received previous speaker fees and/or travel expenses from Novartis Pharma GmbH, Bayer AG, and Alcon Pharma GmbH. Karsten Kortüm received personal consultation fees from Big Picture Medical. Karsten Kortüm received travel expenses from Pharm-Allergan GmbH and Heidelberg Engineering GmbH.Ricarda Schumann received previous speaker fees and travel expenses from Bayer AG, Novartis Pharma GmbH, Pharm-Allergan GmbH, Heidelberg Engineering GmbH, and Carl Zeiss Meditec AG.Siegfried Priglinger received previous speaker fees and/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Pharm-Allergan GmbH.Armin Wolf received previous speaker fees and research funds from Novartis Pharma GmbH, Oertli AG, Bayer AG, Pharm-Allergan GmbH and Alimera Sciences Ophthalmologie GmbH.